Systemic lupus erythematosus had seen only one new biologic approved in over fifty years before Saphnelo (anifrolumab), and the type I interferon pathway had long been a suspected but unproven target.
Unlike therapies aimed at a single cytokine, Saphnelo blocks signaling from all type I interferons by antagonizing their shared receptor. The intravenous antibody is given every four weeks to adults with moderate to severe systemic lupus erythematosus receiving standard therapy.
Saphnelo faces no biosimilar competition and holds twelve years of biologic exclusivity from approval. It competes with belimumab in moderate-to-severe lupus, and its pursuit of subcutaneous dosing and lupus nephritis data are the key developments to track.
